Physician profile
Christopher Kerrigan
NPI 1508253634
$742.91
in general payments reported to CMS, 2019-2025
9 companies · $30.66 in 2025
The $30.66 reported for 2025 was less than what a typical Addiction Medicine (Internal Medicine) provider received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $75.51 · 2023: $116 · 2024: $303 · 2025: $30.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $339.74 | 2021-2024 | Epclusa |
| Nevro Corp. | $144.31 | 2024 | Senza |
| Indivior INC. | $114.47 | 2022-2023 | Sublocade |
| Merck Sharp & Dohme LLC | $34.27 | 2021-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Glaxosmithkline, LLC. | $31.30 | 2021-2023 | Bexsero, Rotarix |
| Braeburn INC. | $30.66 | 2025 | Brixadi |
| Dynavax Technologies Corporation | $17.87 | 2021 | |
| Novo Nordisk INC | $16.75 | 2023 | Rybelsus, Ozempic |
| Sanofi Pasteur INC. | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kerrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.